knowledge -WSS

knowledge

author：explore 2025-09-30 23:20:34 - browse：817

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

hotspot

WSS

Measles policy set amid Florida outbreak alarms vaccine proponents

Researchers tackle phage therapy hurdles for wider adoption

Change Healthcare: What is it, why does its cyberattack matter?

Hospitals are piloting generative AI tools as regulators play catch

Ukraine seeks to reclaim its role as a hub for clinical trials

Biden's 'march

explore

knowledge

entertainment

Medical leaders decry Supreme Court decision on affirmative action

Families look for replacement for GSK asthma drug Flovent

Novavax promises a turnaround & Lilly roils the obesity market

Ozempic has benefits for kidney disease as well as diabetes

Novavax promises a turnaround & Lilly roils the obesity market

Biden's 'march

In Memoriam: Notable people who died in 2023

Change Healthcare: What is it, why does its cyberattack matter?

The cancer drug shortage isn’t new — and neither are the solutions

Measles policy set amid Florida outbreak alarms vaccine proponents

leisure time

Medicare drug price negotiation continues, as pharma counteroffers

Elevance, SCAN deals highlight health insurer acquisition scrutiny

WATCH: Why do our ears pop?

Readout Newsletter: BridgeBio, Akero, and human embryo models

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

focus

hotspot

explore

focus